Rapti Madurawe, PhD FDA

Rapti Madurawe is a branch chief in the Office of New Drug Quality Assessment at the US Food and Drug Administration. Rapti’s branch covers the CMC review of new drug and investigational drug applications for antiviral, anti-microbial, special pathogen, ophthalmic and transplant drug products. Rapti has a Ph.D. in Chemical Engineering and has been at the FDA for 11 years. Prior to joining FDA, she worked in biotechnology and pharmaceutical industry. In addition to her regulatory background, Rapti has experience in leading process development teams, process scale-up, tech transfer and manufacturing trouble shooting.